Rapid computational identification of the targets of protein kinase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 3, 2006, Pages 326-331

  Rockey, William M ^a   Elcock, Adrian H ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Computational; Inhibitor; Kinase; Screening; Selectivity

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 HYDROXYTAMOXIFEN; ALPHA TOCOPHEROL; ERLOTINIB; FASUDIL; GEFITINIB; HYMENIALDISINE; IMATINIB; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; PURVALANOL; SORAFENIB; UNCLASSIFIED DRUG;

BINDING AFFINITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; FLUID RETENTION; HUMAN; IC 50; MATHEMATICAL COMPUTING; MYALGIA; NAUSEA; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER SIMULATION; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646835598     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Klebl BM, Muller G: Second-generation kinase inhibitors. Expert Opin Ther Targets (2005) 9(5):975-993. Contains a table of > 50 kinase inhibitors currently in various stages of clinical trials.
2. McInnes C, Fischer PM: Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Design (2005) 11(14):1845-1863.
3. Rockey WM, Elcock AH: Progress toward virtual screening for drug side effects. Proteins (2002) 48(4):664-671. Describes an early attempt at computational selectivity prediction for kinase inhibitors.
4. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns vs magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov(2004) 3(4):353-359
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 64(19):7099-7109.
6. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated athersclerosis. Arterioscler Thromb Vasc Biol (2004) 24(5):935-942.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 344(14):1031-1037.
8. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S1 Fletcher CD, Fletcher JA, Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-Kit oncoprotein: Biological and clinical implications. Oncogene (2001) 20(36):5054-5058.
9. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H: Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta (2004) 1697(1-2):243-257. Contains a listing of all of the protein kinase structures available in the Protein Data Bank to 2004, which are classified by gene name.
10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
11. Vieth M, Sutherland JJ, Robertson DH, Campbell RM: Klnomics: Characterizing the therapeutically validated kinase space. Drug Disc Today (2005) 10(12):839-846. A useful discussion of the determinants of kinase selectivity.
12. Deng Z, Chuaqui C, Singh J: Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem (2004) 47(2):337-344.
13. Chuaqui C, Deng Z, Singh J: Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. J Med Chem (2005) 48(1):121-133. Describes an interesting approach to characterizing the kinase ATP-binding site.
14. Wong CF, Hunenberger PH, Akamine P, Narayana N, Diller T, McCammon JA, Taylor SS, Xuong NH: Computational analysis of PKA-balanol interactions. J Med Chem (2001) 44(10):1530-1539.
15. Gould C, Wong CF: Designing specific protein kinase inhibitors: Insights from computer simulations and comparative sequence/structure analysis. Pharmacol Ther(2002) 93(2-3):169-178. Describes a study identifying key residues responsible for kinase inhibitor selectivity through virtual mutations and energy calculations.
16. Sheinerman FB, Giraud E, Laoui A: High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol (2005) 352(5):1134-156. Describes a rapid, bioinformatics-based method for computationally predicting the selectivities of kinase inhibitors.
17. Chen YZ, Zhi DG: Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins (2001) 43(2):217-226. Describes an interesting and ambitious attempt to computationally predict the selectivities of vitamin E and 4H-tamoxifen, although there was little conelation observed between these results and experimental results.
18. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using a Lamarcklan genetic algorithm and an empirical binding free energy function. J Comput Chem (1998) 19(14):1639-1662.
19. McGovem SL, Shoichet BK: Information decay In molecular docking screens against holo, apo and modeled conformations of enzymes. J Med Chem (2003) 46(14):2895-2907.
20. Rockey WM, Elcock AH: Structure selection for protein kinase docking and virtual screening: Homology models or crystal structures? Curr Protein Peptide Sci (2006): in press.
21. Rockey VWI, Elcock AH: Rapid computational identification of the targets of protein kinase inhibitors. J Med Chem (2005) 48(12):4138-4152. Describes a novel methodology for predicting the high-affinity targets of small-molecule kinase inhibitors.
22. Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R: Crystal structures of proto-oncogene kinase pim1: A target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol (2005) 348(1):183-193.
23. Caligiuri M, Becker F, Murthi K, Kaplan F, Dedier S, Kaufmann C, Machl A, Zybarth G, Richard J, Bockovich N, Kluge A et al. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death In the absence of cell cycle progression. Chem Biol (2005) 12(11):1103-1115.
24. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotton M, Daub H: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA (2003) 100(26):15434-15439.
25. Daub H, Godl K, Brehmer D, Klebl B, Muller G: Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev Technologies (2004) 2(2):215-224.
26. Valsasina B, Kalisz HM, Isacchi A: Kinase selectivity profiling by inhibitor affinity chromatography. Expert Rev Proteomics (2004) 1(3):303-315.
27. Makara GM, Athanasopoulos J: Improving success rates for lead generation using affinity binding technologies. Curr Opin Biotechnol (2005) 16(6):666-673.
28. Gallion SL, Qian D: Chemical genetic approaches to kinase drug discovery. Curr Opin Drug Discovery Dev (2005) 8(5):638-645.
29. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Beredetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 23(3):329-336. Describes a potentially excellent source for experimental data to validate computational selectivity predictions, although a more thorough comparison of these data with those obtained using more traditional biophysical methods is probably needed to establish it as a true 'gold standard'.
30. Wang Z, Lee J, Cossins AR, Brust M: Microarray-based detection of protein binding and functionality by gold nanoparticle probes. Anal Chem (2005) 77(17):5770-5774.
31. Luo Y: Selectivity assessment of kinase inhibitors: Strategies and challenges. Curr Opin Mol Ther (2005) 7(3):251-255. Comprises the experimental counterpart to this review, containing descriptions of a number of methodologies to assess kinase inhibitors and, importantly, includes brief summaries of their drawbacks.
32. Toogood PL: The kinome is not enough. Chem Biol (2005) 12(10):1057-1058.
33. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Cobum SP, Tang L, Jiang T, Liang DC et al: Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 280(35):31208-31219.
34. O'Hare T, Druker BJ: BIRB-796 is not an effective Abl(T315l) inhibitor. Nat Biotechnol (2005) 23(10):1209-1210.
35. Fabian MA, Biggs WH 3rd, Treiber DK, Zarrinkar PP, Lockhart DJ: BIRB-796 is not an effective Abl(T315t) inhibitor. Nat Biotechnol (2005) 23(10):1210-1211.
36. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 351(Pt 1):95-105.
37. Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: An update. Biochem J (2003) 371(Pt 1):199-204.
38. Lundqvist T: The devil is still in the details - driving early drug discovery forward with biophysical experimental methods. Curr Opin Drug Discovery Dev (2005) 8(4):513-519. Provides a review of the use of biophysical experimental methodologies in drug development. While this review is harsh in its criticism of commonly used computational methods, it is criticism that is not easily dismissed.
39. Upstate Cell Signaling Solutions Inc. Charlottesville, VA, USA (2006). http://www.upstate.com
40. Griffin JD: Interaction maps for kinase inhibitors. Nat Biotechnol (2005) 23(3):308-309.
41. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schaffer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 291(2):680-687.
42. Buolamwini JK, Kamath S: Molecule-kinase interaction map. Nat Biotechnol (2005) 23(11):1346.
43. Fabian MA, Biggs WH, Treiber DK, Zarrinkar PP, Lockhart DJ: Response to molecule-kinase interaction map. Nat Biotechnol (2005) 23(11):1346-1348.
44. Williams M: Systems and integrative biology as alternative guises for pharmacology: Prime time for an iPharm concept? Biochem Pharmacol (2005) 70(12):1707-1716. Provides warning for those researchers who hold high-throughput methodologies in high esteem.
45. Eisenstein M: To affinity and beyond. Nat Methods (2005) 2(4):243.